查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1559715

酵素結合免疫吸附檢測法(ELISA) 測試的全球市場

Enzyme-linked Immunosorbent Assay (Elisa) Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 163 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到2030年，全球酵素結合免疫吸附檢測法（ELISA）測試市場預計將達到16億美元

酵素結合免疫吸附檢測法(Elisa) 檢測的全球市場預計 2023 年為 9.621 億美元，預計到 2030 年將達到 16 億美元，2023-2030 年分析期間複合年成長率為 7.7%。三明治 ELISA 測試是本報告分析的細分市場之一，預計複合年成長率為 7.9%，到分析期結束時將達到 7.841 億美元。在分析期間，間接 ELISA 測試領域的複合年成長率估計為 6.5%。

美國市場預估為2.647億美元，中國預期複合年成長率為7.1%

預計 2023 年美國酵素結合免疫吸附檢測法(ELISA) 檢測市場規模將達 2.647 億美元。中國作為世界第二大經濟體，預計到 2030 年市場規模將達到 2.48 億美元，2023-2030 年分析期間複合年成長率為 7.1%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 7.2% 和 6.1%。在歐洲，德國的複合年成長率預計約為 6.2%。

全球酵素結合免疫吸附檢測法(ELISA) 測試市場 - 主要趨勢與促進因素總結

酵素結合免疫吸附檢測法(ELISA) 檢驗將如何徹底改變診斷與研究？

酵素結合免疫吸附檢測法(ELISA) 測試為檢測和定量蛋白質、荷爾蒙、抗體和其他生物分子提供了靈敏且特異性的方法，正在徹底改變診斷和研究。 ELISA 檢測廣泛應用於臨床實驗室、藥物研究和生物技術，用於診斷感染疾病、監測免疫反應以及檢測與癌症、愛滋病毒和自體免疫疾病等各種健康狀況相關的生物標記。 ELISA 可以準確測量特定抗原和抗體，是醫療保健提供者和研究人員的重要工具。此技術通用性強，可應用於疾病診斷、疫苗研發、藥效檢測、食品安全監測等。隨著對準確、可靠和具有成本效益的診斷的需求不斷增加，ELISA 檢測在推進公共衛生、醫學研究和治療開發方面繼續發揮關鍵作用，為及時有效的干涉提供了基礎。

有哪些技術創新可以提升 ELISA 檢測的功能？

自動化、多重檢測和照護現場(POC) 檢測的創新大大提高了 ELISA 檢測的功能。自動化透過實現高通量篩檢、減少人為錯誤並提高分析速度，徹底改變了 ELISA 工作流程。自動化 ELISA 系統，包括機器人分配、自動盤式分析儀和整合軟體，使實驗室能夠同時處理數百或數千個樣本，從而提高效率並縮短獲得診斷結果的時間。這些系統還標準化了程序，確保不同測試之間的結果一致，並減少體力勞動可能發生的變化。自動化在大規模臨床診斷、藥物研究和流行病學研究中尤其重要，其中快速檢體處理對於及時決策至關重要。

多重分析是 ELISA 技術的另一項重大進步，能夠測量一個樣本中的多種分析物。傳統 ELISA 測試通常一次測量一個目標，而多重 ELISA套件可以同時檢測和量化多個生物標記。這項創新顯著減少了分析血液和血清等複雜生物樣本所需的時間和資源，並在單次檢測中提供全面的資料。多重 ELISA 在需要測量多種細胞激素、荷爾蒙和疾病標記物以了解疾病機制和治療效果的研究中特別有用。此功能在個人化醫療中也很有用，可以同時測量多個生物標記物，為每位患者提供量身定做的治療。

即時 (POC) ELISA 檢測是另一項突破，它允許在傳統實驗室之外進行 ELISA 檢測，例如在診所、偏遠地區或家用。可攜式ELISA 設備旨在通常在幾分鐘內提供現場快速診斷結果。這些系統在資源匱乏的環境和快速診斷和治療至關重要的緊急情況下特別有用。針對 HIV、肝炎和 COVID-19 等疾病的 POC ELISA 檢測的開發極大地擴大了診斷範圍，並改善了服務不足人群的醫療保健服務。這些可攜式系統通常具有簡化的工作流程，可由非專家操作，從而擴大了 ELISA 技術的應用範圍。

奈米技術也提高了 ELISA 測試的靈敏度。金奈米顆粒等奈米材料被納入ELISA檢驗中，以放大訊號並提高檢測極限，從而能夠檢測極低濃度的生物標記。這對於早期疾病檢測尤其重要，識別低濃度的特異性抗原或抗體可以導致早期療育並改善患者預後。靈敏度的提高正在突破 ELISA 檢測的極限，並在分子層面上實現更準確的診斷和研究。

ELISA檢測對疾病診斷和治療有何影響？

ELISA 檢測提供可靠、靈敏且易於使用的方法來檢測血液、唾液、尿液和其他生物樣本中與疾病相關的生物標記物，從而改善疾病診斷，並對治療產生重大影響。 ELISA 的主要優點之一是能夠檢測與感染疾病相關的抗體、抗原和其他蛋白質，使其成為診斷 HIV、肝炎、萊姆病和馬蘇病等疾病的重要工具。例如，在 HIV 診斷中，ELISA 經常被用作初步篩檢測試，以檢測是否有針對該病毒的抗體。早期發現此類感染疾病對於開始治療、預防疾病進展和減少傳播至關重要。

在腫瘤學中，ELISA 測試廣泛用於測量腫瘤標記，例如 PSA（前列腺特異性抗原）和 CA-125（癌症抗原 125），這些標記可用於診斷癌症和監測其進展。透過量化這些標誌物，臨床醫生可以評估腫瘤活動、評估治療效果並檢測復發。 ELISA 測試的高特異性使得即使在複雜的生物樣本中也能準確測量這些標記物，為個人化治療計劃提供重要資訊。同樣，在狼瘡和類風濕性關節炎等自體免疫疾病中，ELISA 可用於檢測特定自體抗體的存在，幫助臨床醫生更有效地診斷和管理這些疾病。

除了診斷之外，ELISA 測試在監測對疫苗和治療的免疫反應方面也發揮著重要作用。例如，在疫苗研究中，ELISA 可以測量疫苗接種後抗體的產生，從而深入了解疫苗功效和保護持續時間。這對於 COVID-19 疫苗的開發尤其重要，其中 ELISA 測試用於評估臨床試驗中的免疫反應。 ELISA 也用於治療藥物監測，透過測量血液中的藥物濃度，幫助臨床醫生確保為患者施用最佳劑量的生物製藥或其他治療藥物。

ELISA 在確定治療策略方面的作用超出了人類醫療保健的範圍。在獸醫學中，ELISA檢測用於檢測牛結核病和禽流感等動物疾病，有助於保護動物健康並防止人畜共通感染疾病傳播給人類。此外，ELISA廣泛應用於食品安全檢測，以檢測過敏原、病原體和污染物，確保食品符合安全標準且不含有害物質。

ELISA 測試提供準確、及時且經濟高效的診斷，可顯著改善患者照護、加強疾病管理並支持各種醫療和科學應用以取得更好的結果。

推動 ELISA 檢測市場成長的趨勢是什麼？

推動 ELISA 檢測市場成長的趨勢包括感染疾病的傳播、癌症早期檢測需求的增加、個人化醫療的擴展以及自動化和多重技術的進步。 HIV、肝炎和最近的 COVID-19 等感染疾病的全球負擔日益增加，是推動 ELISA 檢測需求的最大因素之一。隨著醫療保健系統致力於減少這些疾病的傳播，ELISA 已成為大規模診斷篩檢的重要工具，特別是在高流行地區。為了應對大流行的威脅，對快速、準確和方便的診斷測試的需求將進一步加速 ELISA 測試在臨床和照護現場環境中的採用。

對癌症早期檢測的需求不斷成長也是推動 ELISA 市場的一個主要趨勢。隨著全球癌症發生率持續上升，人們越來越重視開發能夠在治療最有效的早期階段檢測癌症的診斷工具。 ELISA 可以測量腫瘤標記和其他癌症相關蛋白，已成為早期檢測策略的重要組成部分，特別是在前列腺癌、卵巢和乳癌篩檢計畫中。 ELISA與液態切片和分子診斷等其他診斷技術的結合有望提供更全面、更準確的癌症檢測解決方案，並加強其在腫瘤學領域的作用。

個人化醫療的成長也促進了 ELISA 檢測市場的擴大。個人化醫療依賴生物標記的識別來為個別患者量身定做治療方案，而 ELISA 是測量這些生物標記的重要工具。對於自體免疫疾病、心血管疾病、癌症等疾病，個人化治療方案依賴ELISA提供的準確的生物標記資料。隨著精準醫學領域的發展，對支持生物標記發現、藥物開發和個人化治療監測的 ELISA 測試的需求預計將會增加。

自動化和多重技術的進步使 ELISA 測試更加高效和可擴展，進一步推動了成長。自動化 ELISA 系統可降低人事費用，最大限度地減少人為錯誤，並實現高通量測試，這對於大規模臨床診斷和研究至關重要。多重 ELISA 可以在一次測定中測量多種生物標記物，簡化您的工作流程並提供每個樣本的更全面的資料。這些創新使 ELISA 對於希望提高檢測能力同時保持準確性和一致性的實驗室更具吸引力。

法規和行業標準也促進了 ELISA 市場的成長。隨著美國食品藥物管理局(FDA) 和歐洲藥品管理局(EMA) 等監管機構對藥物安全、疫苗功效和診斷準確性實施更嚴格的指導方針，ELISA 檢測作為確保合規性的重要工具變得越來越重要。此外，專注於疾病控制和預防的全球衛生舉措的興起，例如世界衛生組織 (WHO) 的感染疾病控制計劃，增加了對基於 ELISA 的可靠診斷的需求。

這些趨勢凸顯了 ELISA 檢測在診斷、研究和個人化醫療中日益成長的重要性。隨著技術進步不斷提高 ELISA 測試的準確性、速度和可及性，由於日益複雜的醫療保健環境中對準確、可靠和擴充性的診斷解決方案的需求，市場不斷成長，我們相信我們將實現永續成長。

調查企業舉例（共22家）

  • Abcam PLC
  • American Laboratory Products Company（ALPCO）
  • Apollo Diagnostics
  • Assay Biotechnology Company, Inc.
  • Astra Biotech GmbH
  • Avioq, Inc.
  • Awareness Technology, Inc.
  • Axispharm Laboratories Ltd.
  • Biogenes
  • bioMerieux SA

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP11837

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market to Reach US$1.6 Billion by 2030

The global market for Enzyme-linked Immunosorbent Assay (Elisa) Testing estimated at US$962.1 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2023-2030. Sandwich ELISA Testing, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$784.1 Million by the end of the analysis period. Growth in the Indirect ELISA Testing segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$264.7 Million While China is Forecast to Grow at 7.1% CAGR

The Enzyme-linked Immunosorbent Assay (Elisa) Testing market in the U.S. is estimated at US$264.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$248.0 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market - Key Trends and Drivers Summarized

How Is Enzyme-Linked Immunosorbent Assay (ELISA) Testing Revolutionizing Diagnostics and Research?

Enzyme-Linked Immunosorbent Assay (ELISA) testing is revolutionizing diagnostics and research by providing a highly sensitive and specific method for detecting and quantifying proteins, hormones, antibodies, and other biomolecules. Widely used in clinical laboratories, pharmaceutical research, and biotechnology, ELISA tests are essential for diagnosing infectious diseases, monitoring immune responses, and detecting biomarkers related to various health conditions, including cancer, HIV, and autoimmune disorders. The ability to measure specific antigens or antibodies with precision makes ELISA an indispensable tool for both healthcare providers and researchers. The technique’s versatility allows it to be applied in disease diagnostics, vaccine development, drug efficacy testing, and food safety monitoring. As the demand for accurate, reliable, and cost-effective diagnostic methods grows, ELISA testing continues to play a critical role in advancing public health, medical research, and therapeutic development, providing the foundation for timely and effective interventions.

What Innovations Are Enhancing the Functionality of ELISA Testing?

Innovations in automation, multiplexing, and point-of-care (POC) testing are significantly enhancing the functionality of ELISA tests. Automation has transformed ELISA workflows by allowing high-throughput screening, reducing human error, and increasing the speed of analysis. Automated ELISA systems, which include robotic pipetting, automated plate readers, and integrated software, enable laboratories to process hundreds or thousands of samples simultaneously, improving efficiency and reducing turnaround time for diagnostic results. These systems also standardize procedures, ensuring consistent results across different tests and reducing variability that can occur with manual processes. Automation is particularly important in large-scale clinical diagnostics, pharmaceutical research, and epidemiological studies where the rapid processing of samples is essential for timely decision-making.

Multiplexing, which allows multiple analytes to be measured in a single sample, is another major advancement in ELISA technology. Traditional ELISA tests typically measure one target at a time, but multiplex ELISA kits can detect and quantify several biomarkers simultaneously. This innovation significantly reduces the time and resources needed to analyze complex biological samples, such as blood or serum, providing comprehensive data in a single assay. Multiplex ELISA is particularly useful in research settings where multiple cytokines, hormones, or disease markers need to be measured to understand disease mechanisms or treatment efficacy. This capability is also beneficial in personalized medicine, where simultaneous measurement of multiple biomarkers helps tailor treatments to individual patients.

Point-of-care (POC) ELISA testing represents another breakthrough, making it possible to perform ELISA tests outside of traditional laboratories, such as in clinics, remote areas, or even at home. Portable ELISA devices are designed to provide rapid, on-site diagnostic results, often within minutes. These systems are particularly valuable in low-resource settings or during emergencies, where quick diagnosis and treatment are critical. The development of POC ELISA tests for diseases like HIV, hepatitis, and COVID-19 has greatly expanded access to diagnostics, improving healthcare delivery in underserved populations. These portable systems are often user-friendly, with simplified workflows that can be operated by non-specialists, broadening the reach of ELISA technology.

Nanotechnology is also enhancing the sensitivity of ELISA tests. Nanomaterials, such as gold nanoparticles, are being integrated into ELISA assays to amplify signals and improve detection limits, making it possible to detect extremely low concentrations of biomarkers. This is particularly important in early disease detection, where identifying low levels of a specific antigen or antibody can lead to earlier interventions and better patient outcomes. These advancements in sensitivity are helping to push the boundaries of ELISA testing, allowing for more accurate diagnosis and research at the molecular level.

How Does ELISA Testing Impact Disease Diagnosis and Treatment?

ELISA testing has a profound impact on disease diagnosis and treatment by providing a reliable, sensitive, and accessible method for detecting disease-related biomarkers in blood, saliva, urine, or other biological samples. One of the primary benefits of ELISA is its ability to detect antibodies, antigens, and other proteins associated with infectious diseases, making it a crucial tool for diagnosing conditions like HIV, hepatitis, Lyme disease, and COVID-19. In HIV diagnostics, for example, ELISA is often used as an initial screening test to detect the presence of antibodies against the virus. Early detection of such infections is critical for initiating treatment, preventing disease progression, and reducing transmission.

In oncology, ELISA tests are widely used to measure tumor markers, such as PSA (prostate-specific antigen) or CA-125 (cancer antigen 125), which help in diagnosing and monitoring cancer progression. By quantifying these markers, clinicians can assess tumor activity, evaluate the effectiveness of treatments, and detect recurrences. The high specificity of ELISA tests ensures that these markers can be accurately measured even in complex biological samples, providing essential information for personalized treatment planning. Similarly, in autoimmune diseases like lupus or rheumatoid arthritis, ELISA is used to detect the presence of specific autoantibodies, helping clinicians diagnose and manage these conditions more effectively.

In addition to diagnostics, ELISA testing plays a critical role in monitoring the immune response to vaccines and therapies. For example, in vaccine research, ELISA can measure the production of antibodies in response to vaccination, providing insights into vaccine efficacy and duration of protection. This has been particularly important during the development of COVID-19 vaccines, where ELISA tests were used to assess immune responses in clinical trials. ELISA is also used in therapeutic drug monitoring, where it helps clinicians ensure that patients are receiving optimal doses of biologics or other therapies by measuring drug levels in the blood.

ELISA’s role in guiding treatment decisions extends beyond human healthcare. In veterinary medicine, ELISA tests are used to detect diseases in animals, such as bovine tuberculosis or avian influenza, helping to protect animal health and prevent the spread of zoonotic diseases to humans. Additionally, ELISA is widely employed in food safety testing to detect allergens, pathogens, and contaminants, ensuring that food products meet safety standards and are free from harmful substances.

By providing accurate, timely, and cost-effective diagnostics, ELISA testing significantly improves patient care, enhances disease management, and supports better outcomes across a range of medical and scientific applications.

What Trends Are Driving Growth in the ELISA Testing Market?

Several trends are driving growth in the ELISA testing market, including the increasing prevalence of infectious diseases, the rising demand for early cancer detection, the growth of personalized medicine, and advancements in automation and multiplexing technologies. The growing global burden of infectious diseases, such as HIV, hepatitis, and more recently, COVID-19, is one of the most significant factors fueling demand for ELISA tests. As healthcare systems focus on controlling the spread of these diseases, ELISA is a key tool for large-scale diagnostic screening, particularly in high-prevalence regions. The need for rapid, accurate, and accessible diagnostic tests in response to pandemic threats has further accelerated the adoption of ELISA testing in both clinical and point-of-care settings.

The rising demand for early cancer detection is another major trend driving the ELISA market. As cancer rates continue to increase globally, there is a growing emphasis on developing diagnostic tools that can detect cancer at its earliest stages, when treatment is most effective. ELISA’s ability to measure tumor markers and other cancer-related proteins makes it an essential part of early detection strategies, particularly in screening programs for prostate, ovarian, and breast cancer. The integration of ELISA with other diagnostic technologies, such as liquid biopsies and molecular diagnostics, is expected to enhance its role in oncology, offering more comprehensive and accurate cancer detection solutions.

The growth of personalized medicine is also contributing to the expansion of the ELISA testing market. Personalized medicine relies on the identification of biomarkers to tailor treatments to individual patients, and ELISA is a key tool for measuring these biomarkers. In conditions like autoimmune diseases, cardiovascular disorders, and cancers, personalized treatment plans depend on precise biomarker data, which ELISA provides. As the field of precision medicine grows, demand for ELISA testing to support biomarker discovery, drug development, and personalized treatment monitoring is expected to rise.

Advancements in automation and multiplexing technologies are further driving growth by making ELISA testing more efficient and scalable. Automated ELISA systems are reducing labor costs, minimizing human error, and enabling high-throughput testing, which is crucial for large-scale clinical diagnostics and research. Multiplex ELISA, which allows multiple biomarkers to be measured in a single assay, is streamlining workflows and providing more comprehensive data from each sample. These innovations are making ELISA more appealing for laboratories seeking to increase testing capacity while maintaining accuracy and consistency.

Regulatory and industry standards are also contributing to the growth of the ELISA market. As regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), enforce stricter guidelines on drug safety, vaccine efficacy, and diagnostic accuracy, ELISA testing is becoming increasingly important for ensuring compliance. Additionally, the rise of global health initiatives focused on disease control and prevention, such as the World Health Organization’s (WHO) efforts to combat infectious diseases, is increasing the demand for reliable ELISA-based diagnostics.

These trends highlight the growing importance of ELISA testing in diagnostics, research, and personalized medicine. As technological advancements continue to improve the accuracy, speed, and accessibility of ELISA tests, the market is poised for sustained growth, driven by the need for precise, reliable, and scalable diagnostic solutions in an increasingly complex healthcare landscape.

Select Competitors (Total 22 Featured) -

  • Abcam PLC
  • American Laboratory Products Company (ALPCO)
  • Apollo Diagnostics
  • Assay Biotechnology Company, Inc.
  • Astra Biotech GmbH
  • Avioq, Inc.
  • Awareness Technology, Inc.
  • Axispharm Laboratories Ltd.
  • Biogenes
  • bioMerieux SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Bolstering Demand for ELISA Testing
    • Increasing Use of ELISA in Drug Monitoring and Pharmaceutical Applications
    • Impact of Global Health Initiatives on Infectious Disease Detection via ELISA
    • Integration of Automation in ELISA Procedures to Increase Throughput
    • Market Trends Toward Multiplex ELISA for Simultaneous Detection of Multiple Targets
    • Rising Importance of Food Safety Testing Fueling ELISA Adoption
    • Advancements in Biomarker Discovery Driving ELISA Usage in Clinical Trials
    • Consumer Demand for Rapid Diagnostic Tests Influencing ELISA Kit Developments
    • Expansion of Point-of-Care Testing Incorporating ELISA Technologies
    • Future Directions: Integration of AI for Enhanced Data Analysis in ELISA Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Sandwich ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Sandwich ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Sandwich ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Indirect ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Indirect ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Indirect ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Multiple & Portable ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Multiple & Portable ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Multiple & Portable ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers, Research Laboratories and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Enzyme-linked Immunosorbent Assay (Elisa) Testing by Type - Percentage Breakdown of Value Sales for Sandwich ELISA, Indirect ELISA, Multiple & Portable ELISA and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION